Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Rating of “Hold” from Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been assigned an average recommendation of “Hold” from the seven analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $3.75.

Several research firms recently commented on HOWL. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings cut Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th.

Werewolf Therapeutics Stock Performance

HOWL stock opened at $0.35 on Monday. Werewolf Therapeutics has a 12-month low of $0.34 and a 12-month high of $2.38. The company has a market capitalization of $17.07 million, a PE ratio of -0.28 and a beta of 0.29. The business’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.69.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. Research analysts predict that Werewolf Therapeutics will post -1.08 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Ra Capital Management, L.P. sold 376,526 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $0.71, for a total transaction of $267,333.46. Following the completion of the transaction, the insider directly owned 418,813 shares of the company’s stock, valued at approximately $297,357.23. This represents a 47.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Luke Evnin sold 305,741 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $0.70, for a total value of $214,018.70. Following the transaction, the director directly owned 1,273,008 shares of the company’s stock, valued at approximately $891,105.60. This represents a 19.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 3,507,127 shares of company stock valued at $1,879,521. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HOWL. Regal Investment Advisors LLC boosted its position in shares of Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. boosted its position in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics during the 2nd quarter worth about $48,000. AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics during the 1st quarter worth about $79,000. Finally, Bridgeway Capital Management LLC boosted its position in shares of Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares in the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.